5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Cancer Clinical Trial

Official title:

Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00886457
• Other study ID #: NVCI-0725
• Secondary ID: NCI 8224
• Status: Terminated
• Phase: Phase 1
• First received: April 21, 2009
• Last updated: July 19, 2011
• Start date: April 2009
• Est. completion date: October 2010

Study information

• Verified date: July 2011
• Source: Nevada Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess toxicities of a 1-hr infusion of 5-aza-2'-deoxycytidine (decitabine) x 10 days (M-F) plus escalating doses of weekly subcutaneous PEG-interferon-α (PEG-Intron) in patients with metastatic cancer and to identify the maximum tolerated dose of PEG-Intron in this combination. The pre- and post-treatment samples will be evaluated to identify changes in molecular correlates.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: October 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient must have a biopsy proven cancer, which is metastatic or unresectable, for which (in the opinion of the investigator), no curative or more effective treatment exists.

2. Patient must have biopsy accessible tumor and must indicate willingness to undergo biopsies of tumor and normal skin on days 1, 15 and 29.

3. Patient must have measurable disease by RECIST criteria by scans performed within 28 days of study enrollment.

4. Patient may not have untreated brain metastasis. Patients with previously treated brain metastasis must no longer be receiving steroid therapy for the treatment of their brain metastasis.

5. Patient must have a Zubrod performance status of 0 - 2.

6. Prior surgery, radiotherapy or chemotherapy is allowed. The patient must not have received chemotherapy, radiotherapy, surgery, biologic therapy or any other investigational drug for any reason within 28 days prior to registration. Concomitant treatment with other anti-cancer agents or radiotherapy, including investigational agents during the course of study treatment is not allowed.

7. Patients with extensive pelvic irradiation or prolonged nucleoside analogue pretreatment are excluded due to increased risk for hematologic toxicity.

8. Patient must have adequate liver function as defined by a serum bilirubin = 1.5 x the institutional upper limit of normal (IULN), SGOT or SGPT = 2.5 x the institutional upper limit of normal (or = 5 x the institutional upper limit of normal if hepatic metastases is present) obtained within 14 days prior to registration.

9. Patient must have an adequate renal function as defined by a serum creatinine = 1.5 x the institutional upper limit of normal, as well as a calculated or measured creatinine clearance (CrCl) = 50 ml/min.

10. Patient must have an ANC > 1,500/µl, platelet count > 100,000/µl and hemoglobin > 9 gm/dl (this may be achieved by transfusion if needed) obtained within 14 days prior to registration.

11. All patients must be informed of the investigational nature of this study and must provide written acknowledgment of informed consent in accordance with institutional and federal guidelines.

12. Both men and women of all races and ethnic groups are eligible for this trial.

13. Patients must be = 18 years of age.

Exclusion Criteria:

1. Class 3/4 cardiac problems as defined by the New York Heart Association Criteria (e.g., congestive heart failure, myocardial infarction within 2 months of study).

2. Severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, or active uncontrolled infection, e.g., HIV).

3. Patient must not be pregnant or nursing mothers because PEG-Intron or decitabine may be harmful to the developing fetus and newborn. Women/men of reproductive potential must agree to use an effective contraceptive method. Women of reproductive potential must have a negative serum pregnancy test within 7 days prior to registration. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.

4. Medical or psychological conditions that, in the opinion of the investigator, make the patient unable to tolerate or complete the treatment, or to grant reliable informed consent are not eligible for this study.

5. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I, II, or III cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Decitabine and Pegylated Interferon-Alfa 2B
Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .

Locations

Country	Name	City	State
United States	Nevada Cancer Institute	Las Vegas	Nevada

Sponsors (3)

Lead Sponsor	Collaborator
Nevada Cancer Institute	National Institutes of Health (NIH), Schering-Plough

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity based on CTCAE Version 3.0		Daily for 10 days out of 14, and then weekly every 28 days	Yes
Secondary	Genomic DNA methylation and Mage-1 specific promoter methylation in blood cells, tumor and skin		Pretreatment, and then on days 8, 15, 22, and 29	No